SABS
Sab Biotherapeutics
$3.20
+$0.13 (+4.23%)Oct 28, 2026
Key metrics
The numbers that frame SABS today
- Market cap
- $291.16M
- ROIC
- -6.6%
- Div yield
- 0%
- Debt / equity
- 0.0
- 52wk Low
- $2.44
- 52wk High
- $5.15
Growth
Revenue and earnings trend for SABS
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about SABS
Is Sab Biotherapeutics a good buy?
No. Sab Biotherapeutics has poor quality and weak momentum. Both signals point to a weaker setup. Growth looks excellent, which supports the long-term business case, but that is not enough to offset the weak setup. We think Sab Biotherapeutics is selling at a very high price.
What is the market capitalization of SABS?
Sab Biotherapeutics's market capitalization is $291.16M.
What is the 52-week high for SABS stock?
The 52-week high for Sab Biotherapeutics is $5.15. The current close of $3.20 is 37.9% below that high.
What is the 52-week low for SABS stock?
The 52-week low for Sab Biotherapeutics is $2.44. The current close of $3.20 is 31.1% above that low.
Does SABS stock pay dividends?
Sab Biotherapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for SABS?
Sab Biotherapeutics's Debt / Equity ratio is 0.02.